More programs, more candles, more light.

Get the Flash Player to see this player.

Loading the player ...

Targeting the PI3K/mTOR Pathway in Cancer

Christian Rommel, Ph.D., Intellikine

April 21, 2011
34 minutes
Christian Rommel


Christian Rommel serves as Intellikine's Chief Scientific Officer. Dr. Rommel is responsible for the company's research, drug discovery and preclinical development strategy. Prior to joining Intellikine in 2007, Dr. Rommel was Head of Target Research at Merck-Serono in Geneva, Switzerland, where he led several drug development projects and collaborations and provided support for both small molecule and protein-based therapeutics across therapeutic areas. Previously, Dr. Rommel was a senior scientist with Regeneron Pharmaceuticals. He received his doctorate in Molecular Oncology/Signal Transduction from the Max-Planck-Institute, Berlin-Dahlem, Germany and the Institute of Medical Virology, University of Zurich, Switzerland. He has a long standing interest in PI3K/Akt/mTOR as a pathway for therapeutic development. His research led the way for isoform-selective PI3K inhibitors, cross-talk between PI3K and related pathways and the validation of mTOR kinase inhibitors for cancer. He's the editor of "PI3K in Health and Disease" published in 2010.